UroGen Pharma Ltd. is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. UroGen has developed RTGel™ reverse thermal hydrogel, a novel technology that is liquid when chilled, but gels at body temperature. We believe RTGel technology has the potential to be applied to a variety of unmet medical needs where increased exposure to the active drug would improve the therapeutic profile of existing drugs, making local therapy a potentially more effective treatment option. UroGen’s lead investigational candidates, UGN-101 (mitomycin gel) for instillation, and UGN-102 (mitomycin gel) for intravesical instillation, are designed to potentially chemoablate tumors, a method that utilizes intervention without surgical removal or resection, and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and bladder cancer, respectively. UroGen is headquartered in New York, NY with operations in Los Angeles, CA and Israel.
Copyright West LLC. Minimum 15 minutes delayed.